TREATMENT ASSOCIATED NEOPLASMS
\tɹˈiːtmənt ɐsˈə͡ʊsɪˌe͡ɪtɪd nˈiːə͡ʊplˌazəmz], \tɹˈiːtmənt ɐsˈəʊsɪˌeɪtɪd nˈiːəʊplˌazəmz], \t_ɹ_ˈiː_t_m_ə_n_t ɐ_s_ˈəʊ_s_ɪ__ˌeɪ_t_ɪ_d n_ˈiː__əʊ_p_l_ˌa_z_ə_m_z]\
Sort: Oldest first
-
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.